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Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and 
is not silenced by DNA methylation in osteosarcoma. 
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Wnt pathway targeting is of high clinical interest for treating bone loss disorders such as 
osteoporosis. These therapies inhibit the action of negative regulators of osteoblastic 
Wnt signaling. The report that Wnt inhibitory factor 1 (WIF1) was epigenetically silenced 
via promoter DNA methylation in osteosarcoma (OS) raised potential concerns for such 
treatment approaches. Here we confirm that Wif1 expression is frequently reduced in 
OS. However, we demonstrate that silencing is not driven by DNA methylation. 
Treatment of mouse and human OS cells showed that Wif1 expression was robustly 
induced by HDAC inhibition but not by methylation inhibition. Consistent with HDAC 
dependent silencing, the Wif1 locus in OS was characterized by low acetylation levels 
and a bivalent H3K4/H3K27-trimethylation state. Wif1 expression marked late stages of 
normal osteoblast maturation and stratified OS tumors based on differentiation stage 
across species. Culture of OS cells under differentiation inductive conditions increased 
expression of Wif1. Together these results demonstrate that Wif1 is not targeted for 
silencing by DNA methylation in OS. Instead, the reduced expression of Wif1 in OS cells 
is in context with their stage in differentiation.  
 






Osteosarcoma (OS) is the most common primary tumor of bone, and fifth most common 
malignancy in children. Through the use of intensive chemotherapy and improvements in 
surgical resection, the 5-year survival rate for patients with localized disease has 
reached 70% [1]. However, survival rates have failed to substantively improve over the 
past three decades and patients continue to be at high risk of therapy-related 
complications, most notably cardiac toxicity and deafness induced by the 
chemotherapeutic regimes [2]. Metastatic dissemination is also frequent in patients; 
almost 20% of patients present at diagnosis with metastatic disease and almost all 
patients with recurrent disease will develop metastatic lesions [3]. Despite progress in 
our knowledge of OS biology and genetics, 5 year survival rates remain at ~30% for 
patients with metastatic disease [1]. New treatment strategies are needed to improve 
long-term patient survival and improve their post-treatment quality of life.  
OS originates from a disruption in the osteoblastic lineage differentiation process. 
Histologically, OS tumors can resemble different stages of osteoblast maturation. 
Conventional OS, the most common diagnosis, can present as one of three subtypes; 
osteoblastic (~60%), fibroblastic (~10%) and chondroblastic (~10%) [4]. Normal cell 
lineage commitment is intricately linked with epigenetic processes, and gene specific 
epigenetic signatures and chromatin landscapes can define stages of development [5-7]. 
Understanding the epigenetic landscapes of normal cell counterparts will play a role in 
deciphering the epigenomes of cancer cells. 
The mechanisms that underlie the disrupted differentiation process in OS are still 
being elucidated. OS tumors are characterized by multiple somatic chromosomal 
lesions, including localized regions with high levels of mutations (kataegis) and 
chromosomal rearrangements (chromothripsis) [8, 9]. Key genetic events in the genesis 
of OS are disruption of the TP53 and RB1 pathways [10, 11]. Whole genome DNA 
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sequencing also recently identified that recurrent somatic structural variations in the 
ATRX and DLG2 genes are common in OS [8]. Loss or mutation of PRKAR1A, WWOX, 
TWIST, WRN, RECQL4 and amplification of c-FOS, and c-MYC have also been linked 
with OS [12]. It is becoming evident that epigenetic mechanisms also likely play a 
significant role in the initiation and maintenance of OS. Several genes have been 
reported to be epigenetically silenced in human OS, including WIF1, an antagonist of 
Wnt signaling [13, 14].  
Active Wnt signaling is integral to normal osteoblast maturation, driving 
proliferation and differentiation [15]. Inhibition of the Wnt antagonist SOST to stimulate 
anabolic osteoblastic Wnt signaling is being developed for the treatment of the low bone 
mass of osteoporosis [16]. Of note, humans with sclerosteosis or the related van 
Buchem disease, both of which result from mutations reducing SOST expression or 
function, do not appear to be at increased risk of developing OS [17-22]. The report that 
WIF1 was epigenetically silenced in OS, and that its absence could augment OS in 
murine models, has potentially significant clinical implications for the treatment of 
osteoporosis with agents that activate or enhance Wnt signaling in bone [13]. 
To date, all OS epigenetic marker exploratory studies have been conducted in 
established human OS cell lines [13, 23, 24]. No studies have profiled primary OS tissue 
or very early passage cultures derived from OS tumor material. Embryonic stem cells 
(ESC) and tumor cells derived from primary xenograft models have been shown to 
undergo transcriptional and genetic drift with long-term culture [25, 26]. Culture driven 
changes in DNA methylation have also been demonstrated in ESCs, as well as 
divergence of methylation patterning in cancer cell lines and clinical specimens [6, 27, 
28]. Genetically engineered mouse models of human OS that recapitulate the features of 
human OS subtypes enable the study of primary and metastatic disease in low passage 
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cell cultures [29, 30]. Studying OS epigenetic signatures in these primary cultures may 
provide a closer representation of OS than has previously been possible. 
We have made use of primary OS cell cultures derived from mouse OS models 
and normal osteoblasts to understand the regulation of Wif1. We have coupled this with 
human OS cell lines and transcriptional profiles of human OS. Our results demonstrate 
that Wif1 expression is not epigenetically inactivated by DNA methylation in mouse or 
human OS cells as previously reported. We propose that Wif1 expression levels mark 
tumors that are less differentiated and more fibroblastic/pre-osteoblastic without 





Materials and Methods 
Cells 
All cells, unless otherwise specified, were grown in a-modified Eagle’s minimal (aMEM) 
medium supplemented with 10% fetal bovine serum, 2mM GlutaMAX, and penicillin-
streptomycin (normal growth media) at 37°C in a humidified atmosphere with 5% CO2.  
Low passage mouse OS cell cultures and tumors were derived from Osx-Cre p53fl/fl 
pRbfl/fl mice on a C57Bl/6 background (Cre:Lox) as previously described[30]. The 
Kusa4b10 cell line was used in the undifferentiated basal state as a source of pre-
osteoblast cells [31]. Mature osteoblasts were derived by placing Kusa4b10 cells under 
in vitro osteoblast differentiation conditions for 21 days [31] by exposing cells to normal 
growth media supplemented with 1µM ascorbate. Cells were maintained for the times 
indicated with twice weekly media changes. Cells were exposed to normal growth media 
supplemented with 1µM ascorbate and 0.1µM b-Glycerophosphate disodium salt 
hydrate for Alizarin red staining assays [31]. Primary pre-osteoblast and osteoblast cells 
were derived from crushed femur/tibia/iliac crest bones from 5 or 8 week old C57Bl/6 
mice as previously described [32, 33]. Lineage –ve/low CD31-ve Sca-1+ve CD51+ve 
pre-osteoblast cells and Lineage –ve/low CD31-ve Sca-1-ve CD51+ve osteoblast cells 
were purified by flow cytometry (FACSAria, BD Biosciences). WT calvaria cells were 
derived from 2 day old C57Bl/6 pups as previously described [34]. The human OS cell 
line MG63 was acquired from ATCC. The human OS cell lines SAOS-2, G-292 and 
SJSA-1, were a kind gift from Assoc/Prof Damian Myers (Department of Surgery, St. 
Vincent’s Hospital, Fitzroy, Australia), who purchased them from ATCC. 
 
Bisulphite clonal sequencing 
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Bisulphite clonal sequencing was performed as previously described [35, 36] with some 
modifications. Genomic DNA was extracted using a DNeasy Blood and Tissue kit 
(Qiagen) as per the manufacturer’s instructions. Genomic DNA was bisulphite converted 
using an EZ DNA Methylation-Gold kitÔ (ZYMO Research) according to the 
manufacturers instructions. Nested bisulphite clonal sequencing primers were designed 
using MethPrimer publicly available online software. Primer sequences recognizing 
bisulphite converted DNA that encompassed two overlapping regions of the locus are 
listed in Supplementary table 1. PCR reactions were conducted in triplicate each time 
and combined to reduce potential amplification bias. PCR fragments were cloned into a 
pGEMÒ-T vector (Promega) and propogated in TOP10 chemically competent E.coli. 
Three to six clones from each sample were randomly chosen and sequenced. 
 
Drug treatments 
5-aza-2’-deoxycytidine (5Aza) (Sigma Aldrich) was applied at 100nM in mouse cells or 
5µM in human cells every 24 hours for 3 consecutive days. Trichostatin A (TSA) 
(Upstate, Millipore) was applied (100ng/ml) for 24 hours either alone or in combination 
with 5Aza in the final 24 hours of a 3-day assay.  
 
RNA extraction, cDNA synthesis, QPCR 
Total RNA used for microarray analyses was extracted using TRIzol reagent (Ambion). 
The aqueous RNA phase was isolated by chloroform separation and further purified by 
an RNeasy mini column kit (Qiagen) as per the manufacturers instructions. Total RNA 
used for QPCR analyses was extracted using an RNeasy mini or micro column kit 
(Qiagen) as per the manufacturers instructions. cDNA was synthesized using an 
AffinityScript QPCR cDNA synthesis kit (Agilent) as per the manufacturers instructions. 
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Gene expression was quantified by realtime PCR (QPCR) using SYBR Green (Brilliant II 
SYBRÒ Green, Agilent) and oligonucleotide primers with a Mx3000P thermocycler 
(Stratagene) with MxPro software (Stratagene). Oligonucleotide primer sequences are 
listed in Supplementary table 1. Gene relative expression quantitation was calculated 
using the 2-DCT method, normalized to Hprt expression. Primer specificity was verified 




RNA from mouse Cre:Lox fibroblastic OS cell cultures, pre-osteoblastic cells 
(undifferentiated Kusa4b10 cells) and osteoblast cells (derived by in vitro differentiation 
of Kusa4b10 cells) cells were hybridized to Affymetrix Mouse Gene 1.0ST microarrays at 
the Ramaciotti Centre for Gene Function Analysis at the University of New South Wales, 
Australia. The raw data has been uploaded to the Gene Expression Omnibus (GEO). 
Publicly available gene expression data from human OS samples and mouse Cre:Lox 
(fibroblastic) and shRNA (osteoblastic) OS subtype tumors were retrieved from GEO 
(accession numbers GSE30699 [37] and GSE38742 [29]). Raw data were normalized 
using RMA in GenePattern[38]. Probes were considered detected if expression was 
greater than the median of the control probes. Differentially expressed genes were 
analyzed using the LIMMA algorithm [39]. 
 
Chromatin immunoprecipitation (ChIP) 
ChIP assays were performed as previously described [36, 40, 41]. ChIP assays were 
performed on three different mouse OS cell cultures and were compared to three 
independently derived samples each of pre-osteoblast and osteoblast cells derived from 
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Kusa4b10 cells. Antibodies directed against H3K4trimethylation (Active Motif, 
No.39159), H3K27trimethylation (Millipore, No.07-449), diacetylated H3 (K9/K14) 
(Millipore, No.06-599) and normal rabbit IgG (Millipore, No.12-370) were used. 
Enrichment was quantified by QPCR. ChIP relative enrichment was determined by the 2-
DCT(bound-input) method and normalized to a control region in the Gapdh gene. Mean 
relative enrichment was determined from 3 independent osteoblast and pre-osteoblast 
samples, compared to 3 different mouse OS cell cultures.  
 
Statistical analyses 
Experiments are represented as mean±SEM (error bars) calculated from a minimum of 
two biological replicates unless otherwise stated. Student’s t test was used to compare 
two groups and one-way ANOVA was used to compare a response over multiple time 





Wif1 is downregulated in mouse OS 
To identify OS targets that are epigenetically deregulated we performed gene 
expression profiling of three independent early passage primary mouse OS cell cultures 
(494H, 493H, 716H) and mouse osteoblasts. The OS cell cultures were established from 
a mouse model of fibroblastic OS generated by osteoblast restricted deletion of Trp53 
and Rb1 [30] and were less than 8 passages from isolation from the primary tumor. 
Comparison of significantly differentially expressed genes (absolute log fold change >1.5 
and p<0.05) identified 789 transcripts that are deregulated in OS compared to 
osteoblasts that were derived by differentiation of pre-osteoblastic Kusa4b10 cells (Fig. 
1A). Of interest, we noted that Wif1 was one of the targets significantly downregulated in 
the murine OS cells (Fig. 1A), consistent with that reported in human OS [13, 14]. 
Independent profiling of primary mouse OS cell cultures and primary whole mouse OS 
tumors confirmed that Wif1 was repressed in OS cells (Fig. 1B-C). Wif1 expression was 
reduced in OS cells when compared to in vitro differentiated osteoblasts and FACS-
isolated mature osteoblasts from wildtype (WT) mouse long bones (Fig. 1B-C). Taken 
together, the mouse OS cells exhibit a deregulated transcriptome, and Wif1 is 
downregulated in murine OS cells consistent with findings in human OS [13, 14].  
 
Low expression of Wif1 in OS cells is controlled independently of DNA 
methylation 
 WIF1 has been reported to be epigenetically silenced by DNA methylation in 
human OS [13, 14]. As the transcriptional regulation of Wif1 in OS was conserved 
across species, we sought to establish if it was also epigenetically conserved. 
Surprisingly, however, bisulphite clonal sequencing of the Wif1 CpG island promoter 
region showed the locus is hypomethylated in mouse OS cells, similar to profiles in 
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osteoblast cells and pre-osteoblast cells derived from Kusa4b10 cells (Fig. 2A). In 
contrast to the hypomethylated Wif1 locus, the Line-1 element in the OS cells was 
heavily methylated as expected[42], demonstrating the sensitivity of the assay 
(Supplementary Figure 1). The Wif1 hypomethylated status in mouse osteoblasts and 
primary OS cell cultures also contrasted with that previously reported in human OS. 
Consistent with the hypomethylated status of the Wif1 locus in murine OS, treatment 
with the demethylating agent 5-aza-2`-deoxycytidine (5Aza) failed to induce Wif1 
expression (Fig. 2B). Treatment with the HDAC inhibitor Trichostatin A (TSA), however, 
elicited a strong induction of Wif1 expression in the mouse OS cultures. The level of 
induction of Wif1 was not further enhanced by the combined treatment of 5Aza with TSA 
(Fig. 2B), supporting the conclusion that Wif1 silencing in mouse OS cells is not driven 
by DNA methylation. TSA and 5Aza treatment of pre-osteoblastic Kusa4b10 cells and 
primary calvarial osteoblastic cells elicited similar Wif1 expression responses to the 
mouse OS cells (Fig. 2C-D). The observed equivalent induction in Wif1 expression 
suggested similar epigenetic mechanisms may control Wif1 in OS cells and normal 
osteoblastic cells.   
WIF1 has been shown to be responsive to 5Aza in several human OS cell lines 
[13, 14], although its responsiveness to HDAC inhibition was not tested. The differential 
methylation of 4 CpG dinucleotides located 200bp to 500bp upstream from the 
transcription start site was proposed to mediate WIF1 silencing in human OS cells [13]. 
We treated four different human OS cell lines (SAOS-2, G292, MG63, SJSA-1) with TSA 
and found WIF1 expression was rapidly induced, similar to results obtained from mouse 
OS cultures (Fig. 2E). Surprisingly, we failed to reproduce the robust induction in WIF1 
expression in response to 5Aza treatment that has been previously reported, despite 
using comparable treatment conditions (5µM over 3 days) [13, 14]. Furthermore, 
combined treatment with 5Aza together with TSA failed to induce expression of WIF1 
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significantly beyond levels achieved by TSA treatment alone (Fig. 2E). Collectively the 
results from murine and human OS cells indicated that methylation may not be involved 
in regulating WIF1 expression in human OS cells. 
A hypoacetylated bivalent chromatin state controls Wif1 expression 
Robust induction of Wif1 expression in mouse and human OS cell lines with TSA 
treatment suggested a repressive histone chromatin state was mechanistically involved 
in Wif1 silencing. To examine the histone modification status of Wif1 in OS we mapped 
the relative enrichment of the repressive histone mark H3K27trimethylation (H3K27tri) 
and the active histone marks H3K4trimethylation (H3K4tri) and H3 diacetylation of 
K9/K14 (H3Ac) across the Wif1 locus in three primary mouse OS cell cultures and 
normal osteoblast and pre-osteoblast cells using chromatin immunoprecipitation (ChIP). 
Wif1 silencing in OS cells correlated with higher enrichment of the repressive H3K27tri 
mark and lower enrichment of the active H3Ac mark within 400bp of the TSS in all three 
mouse OS tumors compared to normal osteoblasts (Fig. 3). Interestingly, both OS cells 
and normal osteoblasts showed a similar enrichment of the active H3K4tri mark across 
the Wif1 locus, indicating the silenced Wif1 locus is bivalently marked in OS cells. H3Ac 
mapping of pre-osteoblast cells demonstrated that normal osteoblast maturation is 
associated with a gain in H3Ac at the Wif1 locus (Fig. 3). The pre-osteoblasts had a 
similar H3Ac landscape to OS cells, consistent with both cell types lacking Wif1 
expression (Fig. 3, Fig. 1 and Fig. 5A-B).  
 
Wif1 expression marks mature osteoblastic differentiated states 
Wnt signaling plays an important role in normal osteoblast differentiation [15] and 
developmentally poised genes are characteristically bivalently marked [43, 44]. We 
hypothesized that Wif1 expression in OS may be reduced due to the differentiation stage 
of the tumor. Microarray profiling showed the osteoblast gene expression profile in the 
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mouse OS cells mimicked the osteoblastic patterning in normal pre-osteoblastic 
undifferentiated Kusa4b10 cells (Fig. 4A-B). Low expression of Wif1 in pre-osteoblastic 
cells correlated with low expression of Phex, Bglap, Dmp1 and Sost, genes that mark 
late stages of osteoblast maturation. As pre-osteoblastic cells were induced to 
maturation, a gain in Wif1 expression coincided with increased expression of well-
defined markers of osteoblast differentiation (Fig. 4A). A similarly repressed mature 
osteoblastic gene expression profile, with reduced Wif1 expression, was evident when 
the fibroblastic OS cells were compared to the in vitro differentiated mature osteoblasts 
(Fig. 4B).  
The mouse OS cell cultures used in our analyses were obtained from a model of 
OS (Cre:Lox) that most closely approximates the fibroblastic or undifferentiated form of 
OS in humans [29, 30]. We recently developed a new mouse model of OS generated by 
shRNA driven knockdown of Trp53 in the osteoblast lineage [29]. Histological, QPCR, 
and FACS cell surface profile analyses of tumors derived from the shRNA OS model 
were all characteristic of the osteoblastic OS subtype. The tumor cells in the Cre:lox 
model are enriched in pre-osteoblasts whilst those derived from the shRNA OS model 
are predominantly mature osteoblasts. Interestingly, microarray profiling identified 
expression of Wif1 as one of the key genes to distinguish the osteoblastic and 
fibroblastic OS subtype models [29] (Fig. 4C). Reduced Wif1 expression in the 
fibroblastic OS cells correlated with the repressed mature osteoblastic gene profile 
(Sost, Dmp1, Phex, Bglap) evident in these OS cells [29] (Fig. 4C).  
To further examine the association of WIF1 expression with osteoblast 
differentiation stage in OS we examined the relationship between WIF1 expression and 
markers of osteoblastic differentiation in a previously published human OS microarray 
dataset [37]. WIF1 expression was low in most tumors, however tumors that did express 
WIF1 clustered in mature tumor phenotypes, coincident with other markers of the mature 
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osteoblastic phenotype (Fig. 4D). The segregation of WIF1 expression with osteoblastic 
markers of late stages of maturation was consistent with a previous report in human OS 
[13]. These data suggest that WIF1 expression status may mark later stages of 
osteoblast differentiation and therefore distinguishes poorly differentiated OS tumors 
from more differentiated OS tumors. 
 
Induction of Wif1 expression in OS cells under differentiation conditions  
To further examine whether the heterogeneous Wif1 expression pattern seen in 
OS tumors is driven by their osteoblastic differentiation status, we examined Wif1 
expression during normal osteoblast differentiation. Under in vitro osteoblastic 
differentiation conditions, Wif1 expression in the Kusa4b10 pre-osteoblastic cell line was 
almost undetectable in the early stages of differentiation when these cells retain 
adipogenic potential (Fig. 5A). As lineage commitment and differentiation proceeded 
there was a robust increase in Wif1 expression levels. The increase in Wif1 expression 
paralleled the increased expression of classic markers of osteoblast maturation such as 
Pthr1 and Bglap (Fig. 5A). Similarly, expression profiling of primary FACS isolated 
immature pre-osteoblast cells and mature osteoblast cells isolated from WT mouse long 
bones demonstrated Wif1 expression levels could distinguish mature osteoblasts from 
immature pre-osteoblast cells, along with other late markers including Pthr1 and Bglap 
(Fig. 5B). This demonstrates that Wif1 expression is a marker of mature osteoblast cells, 
consistent with findings in human osteoblast cells [13].  
If Wif1 expression marks the maturation stage at which the OS cell is blocked, 
we reasoned that Wif1 expression should be increased in OS cells if they could be 
forced into a more mature differentiation stage. We placed four primary mouse OS cell 
cultures and four human OS cell lines under in vitro osteoblastic differentiation 
conditions. As evidenced by increased alizarin red staining of mineralized nodules, all of 
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the human and mouse OS cell lines underwent maturation to some extent (Fig. 5C-D 
and Supplementary Fig. 2A-B). Correspondingly, we noted increased Wif1 expression in 
all cultures and cell lines as they differentiated (Fig. 5E and Supplementary Fig. 2C), 
similar to pre-osteoblastic cells undergoing maturation. Collectively the results from 
mouse and human OS and normal osteoblasts demonstrates that WIF1 marks late 







Changes in gene expression during tumorigenesis can be mediated by a number of 
mechanisms. Of these, DNA methylation is becoming increasingly associated with 
silencing of tumor suppressor genes. One attractive feature of DNA methylation is the 
possible reversal of this state using small molecule inhibitors. An understanding of the 
key targets for DNA-methylation in OS may provide a rationale for the application of 
demethylating agents in this tumor type. Additionally, a better understanding of the 
targets of DNA methylation may reveal important biology relevant to the initiation and 
maintenance of OS. WIF1 and other Wnt antagonists are frequently targeted for 
epigenetic inactivation by DNA methylation in many human cancers [45-49]. It had been 
proposed that DNA methylation dependent silencing of WIF1 in OS was biologically 
meaningful and its loss predisposed osteoblasts to transformation in experimental 
models [13]. The present work demonstrates WIF1 is not silenced by DNA methylation in 
human and mouse OS. Instead, silencing is driven by a histone modification chromatin 
profile that is conducive to activation by HDAC inhibition and normal osteoblastic 
maturation cues. WIF1 expression was shown to tightly couple with osteoblastic 
maturation. We propose that WIF1 expression is low/reduced in OS cells because they 
are stalled in the normal osteoblastic differentiation program.  
WIF1 was previously reported to be epigenetically silenced by DNA methylation 
in human OS cell lines and tumors [13, 14]. The present study, and a separate genome-
wide MeDIP-chip methylation profiling study of human OS cell lines [24], did not identify 
WIF1 as a differentially methylated target in OS. We believe these opposing results may 
stem from the type of assays performed by others [13, 14] and their interpretation of the 
results. Firstly, WIF1 expression was not activated by 5Aza treatment in all cell lines with 
a methylation signature [13, 14]. Secondly, 4 CpG sites located in a region spanning 
200bp to 500bp upstream of the WIF1 transcription start site were proposed to mediate 
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the silencing. However, the methylation pattern did not appear to always correlate with 
the 5Aza mediated WIF1 response OS cell lines examined [13]. It was not examined 
whether 5Aza induced activation of WIF1 expression correlated with the demethylation 
of the 4 CpG sites. These experiments would have mechanistically linked differential 
methylation of the 4 CpG sites with transcriptional silencing.  
5Aza has been shown to reactivate genes independent of DNA demethylation 
effects, including the Wnt antagonist DKK1 in glioblastoma multiforme tumors [50]. The 
previous studies also did not examine the effects of HDAC inhibition [13, 14]. We have 
demonstrated that WIF1 can be activated by TSA and osteoblastic differentiation cues in 
OS cell lines previously examined (G292, SJSA-1, SAOS-2), two of which were reported 
to have WIF1 activation following 5Aza treatment. Recent evidence from a large scale 
study of 19 human OS cell lines [23] would suggest WIF1 methylation differences may 
not be functionally relevant. Despite being identified as a differentially methylated gene, 
WIF1 was not identified to be differentially expressed between the 19 OS cell lines and 
the normal osteoblast controls [23]. Finally, Kansara and colleagues reported that 5Aza 
treatment of the human OS cell lines induced osteoblastic differentiation as measured by 
increased alkaline phosphatase staining and mineralization [13]. In light of our current 
findings that WIF1 expression is tightly coupled to osteoblastic differentiation, 5Aza 
treatment may have activated WIF1 expression indirectly by inducing maturation of the 
OS cell lines rather than having a direct effect on WIF1. Indeed, pretreatment of human 
bone marrow stromal cells with 5Aza has been shown to enhance osteogenic 
differentiation [51].  
WIF1 silencing has been shown to be driven by HDAC dependent mechanisms 
in glioblastoma multiforme tumors [50]. We have demonstrated that the silenced Wif1 
promoter is hypoacetylated in OS compared to normal Wif1 expressing osteoblasts. 
Consistent with a histone modification driven mechanism of silencing, robust increases 
 18	
in Wif1 expression were achieved in OS and normal pre-osteoblast cells by treatment 
with TSA. Interestingly, we also demonstrate Wif1 is bivalently marked in OS cells. 
Bivalent states have been shown to mark developmentally poised genes in embryonic 
stem cells and are progressively lost during cellular differentiation [44]. In Wilms kidney 
tumors, bivalent domains marked the stalled developmental gene program that is 
upregulated during normal kidney differentiation, but is maintained in a repressed state 
in Wilms tumors, reminiscent of kidney progenitor cells [43]. Therefore it is perhaps not 
surprising that the Wif1 locus was bivalently marked in OS cells that are stalled in an 
osteoblastic differentiation program. These results demonstrate the importance of 
assessing the status of genes across a differentiation cascade. Most tumors show an 
impairment of differentiation and the patterns of gene expression may be a consequence 
of this rather than a driver of the tumor process. 
The initial report of WIF1 being epigenetically inactivated by DNA methylation in 
OS [13] raised concerns for the clinical use of Wnt agonists in bone loss disorders due to 
the possible increased risk of OS development. Herein we show these concerns, as far 
as they relate to WIF1, are perhaps less significant than originally proposed. WIF1 
expression, although often low/reduced in OS due to coupling of its expression with 
osteoblast maturation, is not epigenetically inactivated in OS by DNA methylation, but 
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Figure 1: Wif1 expression is downregulated in mouse OS cells compared to 
mature osteoblasts. (A) Heatmap representation of 789 transcripts differentially 
expressed (absolute log fold change >1.5 and p<0.05) in mouse OS cell cultures 
compared to three independently derived mature osteoblast samples (OB1,2,3) (in vitro 
differentiated pre-osteoblastic Kusa4b10 cells). The heatmap is colored based on 
relative values using the row minimum and row maximum. Wif1 is highlighted and is 
downregulated in mouse OS cells. (B) QPCR analysis of Wif1 expression levels in 
mature osteoblast samples (in vitro differentiated Kusa4b10 pre-osteoblastic cells) and 
mouse OS cell cultures. Mean relative expression ±SEM (n=3-6). Asterix denotes 
statistical significance determined by Student’s t test, ** p<0.01. (C) QPCR analysis of 
Wif1 expression levels in primary osteoblastic cells (derived from WT mouse long bones) 
and whole mouse OS tumors. Mean relative expression ±SEM (n=5-9). Asterix denotes 
statistical significance determined by Student’s t test, **** p<0.0001.     
 
Figure 2: Wif1 is hypomethylated in OS cells and is upregulated by HDAC 
inhibition. (A) Schematic of the Wif1 locus analyzed by bisulphite sequencing. The 
spatial positioning of the CpG dinucleotides assessed are represented as lollipops. The 
hypomethylation status of Wif1 in each culture is represented by the colored grids. Each 
row of boxes represents a single cloned allele. Each box represents a single CpG 
dinucleotide that is methylated (dark grey) or unmethylated (white).  Each group of 3-6 
cloned alleles represents an independent DNA sample derived from pre-osteoblastic 
cells (undifferentiated Kusa4b10 cells), osteoblast cells (in vitro differentiated Kusa4b10 
cells) or 3 independent mouse OS cell cultures (494H, 493H, 202V). (B-E) Treatment of 
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OS and osteoblastic cells with inhibitors of HDACs and DNA methylation. Untreated cells 
(U) were compared to cells treated with the HDAC inhibitor TSA (T), the DNA 
methylation inhibitor 5-aza-2’-deoxycytidine (A), or a combination of both compounds 
(A+T). Values represent mean Wif1 relative expression ±SEM (n=2-3). Asterix denotes 
statistical significance determined by Student’s t test, * p<0.05, ** p<0.01, *** p<0.001. 
(B) Wif1 expression levels in mouse OS cell cultures. (C) Wif1 expression levels in 
Kusab410 pre-osteoblastic (Pre-OB) cells. (D) Wif1 expression levels in primary mouse 
calvarial osteoblastic (OB) cells. (E) WIF1 expression in human OS cells.   
 
 
Figure 3: The Wif1 promoter in OS cells is associated with a bivalent 
H3K27tri/H3K4tri and reduced H3Ac histone modification state. Schematic of the 
mouse Wif1 locus with transcription start site (TSS) and translation start site (ATG) 
positioning shown based on the mouse mm8 genome build.  H3K27tri, H3K4tri and 
H3Ac modifications were mapped across four regions (numbered 1-4, positions relative 
to ATG). Relative enrichment at the Wif1 locus was normalized to levels detected at a 
control locus region (Gapdh coding region). Values are mean relative enrichment ± SEM 
for three osteoblast cell samples (OB) (in vitro differentiated Kusa4b10 cells), 3 pre-
osteoblast cell samples (Pre-OB) (undifferentiated Kusa4b10 cells), and 3 different 
mouse OS cell cultures (OS); * p<0.05, ** p< 0.01 derived by Student’s t test. 
 
 
Figure 4: Wif1 expression correlates with OS tumor subtype and maturity status. 
(A) Heatmap representation of osteoblastic marker gene set expression in mouse pre-
osteoblastic cells (undifferentiated Kusa4b10 cells) and mature osteoblast cells (derived 
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by in vitro differentiation of Kusa4b10 pre-osteoblastic cells). The heatmap is colored 
based on relative values using the row minimm and row maximum. (B) Heatmap 
representation of osteoblastic marker gene set expression in mouse fibroblastic 
(Cre:Lox) OS cell cultures and mature osteoblast cells (derived by in vitro differentiation 
of Kusa4b10 pre-osteoblastic cells). The heatmap is colored based on relative values 
using the row minimm and row maximum. (C) Heatmap representation of osteoblastic 
marker gene set expression in OS tumors derived from mouse osteoblastic (shRNA) and 
mouse fibroblastic (Cre:Lox) OS models. The heatmap is colored based on relative 
values using the row minimum and row maximum. (D) WIF1 expression segregates 
mature osteoblastic phenotypes from immature/fibroblastic OS phenotypes. Heatmap 
representation of osteoblastic marker gene set expression in a panel of primary human 
fibroblastic (yellow circle), chondroblastic (blue circle) and osteoblastic (black circle) OS 
tumors. Samples were clustered by Euclidian distance and colored based on relative 
values using the row minimum and row maximum. 
 
Figure 5: Wif1 expression is acquired late in normal osteoblast lineage 
commitment and is induced in mouse and human OS cells under osteoblastic 
maturation conditions. (A-B) QPCR analysis of Wif1 expression and early (Runx2, 
Sp7), intermediate (Pth1r, Alpl) and late (Bglap) osteoblastic gene expression markers. 
Values are mean relative expression ±SEM. Asterix denotes statistical significance 
determined by one-way AVOVA or Student’s t test, * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. (A) Wif1 and osteoblastic gene expression profiles in pre-osteoblastic 
Kusa4b10 cells undergoing in vitro osteoblast differentiation (n=3). (B) Wif1 and 
osteoblastic gene expression profiles in pre-osteoblast (Pre-OB) and osteoblast (OB) 
cells isolated from 8 week old wild type C57BL6 mouse long bones (n=4-7). (C) Alizarin 
red staining of mineralized nodules in mouse (716H and 493H) and human (SAOS-2, 
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SJSA-1) OS cell cultures grown under osteoblastic conditions over 21 days. (D) 
Quantitation of mineralization in mouse (716H and 493H) and human OS (SAOS-2, 
SJSA-1) cell culture over 21 days. Values are mean eluted alizarin red concentration 
(µM) ±SEM. Data is from 5 separate assays from an individual experiment and is 
representative of 2 independent experiments. Asterix denotes statistical significance 
determined by one-way AVOVA, * p<0.05, ** p<0.01, **** p<0.0001. (E) Quantitation of 
Wif1 expression in mouse (716H and 493H) and human OS (SAOS-2, SJSA-1) cell 
cultures grown under osteoblastic conditions over 21 days. Values are mean fold change 
in Wif1 expression (compared to day 0) ± SEM (n=2-3). Asterix denotes statistical 
significance determined by one-way AVOVA, * p<0.05, ** p<0.01, **** p<0.0001.  
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Supplementary Figure 2: The Line-1 repetitive element is hypermethylated in 
mouse OS. Schematic of the mouse Line-1 repetitive element showing the 249bp region 
in the 5’UTR that was analyzed by bisulphite clonal sequencing. The spatial positioning 
of the nine CpG dinucleotides assessed in the 249bp region are represented by 
lollipops. The methylation status of the Line-1 element in 494H mouse fibroblastic OS 
cell culture is represented by the colored grid. Each row of boxes represents a single 
cloned allele. Each box represents a single CpG dinucleotide that is methylated (dark 


















































































































Supplementary Figure 2: WIF1 expression is induced in mouse and human OS 
cells grown under osteoblastic maturation conditions. (A) Alizarin red staining of 
mineralized nodules in mouse (202V and 494H) and human (G292, MG63) OS cell 
cultures grown under osteoblastic conditions over 21 days. (B) Quantitation of 
mineralization in mouse (202V and 494H) and human OS (G292, MG63) cell cultures 
over 21 days. Values are mean eluted alizarin red concentration (µM) ± SEM. Data is 
from 5 separate assays from an individual experiment and is representative of 2 
independent experiments. Asterix denotes statistical significance determined by one-way 
AVOVA, * p<0.05, ** p<0.01, **** p<0.0001. (C) Quantitation of Wif1 expression in 
mouse (202V and 494H) and human OS (G292, MG63) cell cultures grown under 
osteoblastic conditions over 21 days. Values are mean fold change in Wif1 expression 
(compared to day 0) ± SEM (n=2-3). Asterix denotes statistical significance determined 
by one-way AVOVA, * p<0.05, ** p<0.01, **** p<0.0001.  
	  
Supplementary Table 1 – Primer Sequences
	  
Application Gene / chromatin region Species Forward Sequence (5'-3') Reverse Sequence (5'-3') Reference 
Bisulphite Clonal Sequencing Wif1 F1/R1 Mouse TTTTTTAAATTTAATTTTAAGGGGAGTTT AAACCACTAAAAAAATACAAATACC Current 
Bisulphite Clonal Sequencing Wif1 F2/R2 Mouse AATTGGGTTATTAAGAAGATAAATTA CTAACAAAACTAACAATACCAACAC Current 
Bisulphite Clonal Sequencing Wif1 F3/R3 Mouse TTGGTATTGTTAGTTTTGTTAGTAT TCTCCTCAAATAACTACCCTACATC Current 
    
ChIP assays Wif1 Region 1 Mouse AGCAACCCCCGAGGATTCTGGG GCTCGCTAAGACGACAAGCGC Current 
ChIP assays Wif1 Region 2 Mouse TGTCTCTTCGGGCGGCAGGA TCGCCTGCGCCAGGTGAATG Current 
ChIP assays Wif1 Region 3 Mouse CCGCGGTTCCTCCCTCTCGA GGCAATGCCAGCACGTCCCA Current 
ChIP assays Wif1 Region 4 Mouse AGCAGCACAGGTTGGGTCGC GCGCGAAAGCAGGGAAGGCT Current 
ChIP assays Gapdh Mouse CGAAGAACAACGAGGAGAAGATC CGAACCTCTCCCCATTATTGAA Current 
    
Gene Expression Hprt Mouse TGATTAGCGATGATGAACCAG AGAGGGCCACAATGTGATG Current 
Gene Expression Wif1 Mouse AAATGCCCCCAACCCTGCCG CAGGCTCGCAGACGGGCTTA Current 
Gene Expression Runx2 Mouse CTCCGCTGTTATGAAAAACC TGAAACTCTTGCCTCGTCC Current 
Gene Expression Sp7 Mouse TATGCTCCGACCTCCTCAAC AATAAGATTGGGAAGCAGAAAG Current 
Gene Expression Alp Mouse AAACCCAGACACAAGCATTCC TCCACCAGCAAGAAGAAGCC Current 
Gene Expression Pth1r Mouse TTCCAGGGATTTTTTGTTGC AGTCCAATGCCAGTGTCCAG Current 
Gene Expression Bglap Mouse TCTCTCTGACCTCACAGATCCC TACCTTATTGCCCTCCTGCTTG Current 
    
Gene Expression HPRT1 Human TGATTAGCGATGATGAACCAG AGAGGGCCACAATGTGATG Current 
Gene Expression WIF1 Human TGAATTTTACCTGGCAAGCTG GGACATTGACGGTTGGATCT Kansara et al (2009) JCI, 119(4):837-51 
